Advanced Solid Tumor Clinical Trials & Research at St. Joseph Health Medical Group

St. Joseph Health Medical Group is currently enrolling patients for the following advanced solid tumor clinical trials:


A Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination with M9241 (NHS-IL12) in Subjects with Locally Advanced, Unresectable, or Metastatic Solid Tumors (EMD 0031)

Treatment agent: Avelumab + NHS-IL12 (interleukin-12 Ab conjugate)
PI: Thomas Stanton, MD
Study Coordinator: Camille Shaffer // Camille.Shaffer@stjoe.org // (707) 521-3809
Resources and Links: clinicaltrials.gov NCT No: NCT02994953


eFT508 in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone (eFFECTOR)

Treatment agent: eFT508 + PD-1/PD-L1 Inhibitor Therapy
PI: Thomas Stanton, MD
Study Coordinator: Camille Shaffer // Camille.Shaffer@stjoe.org // (707) 521-3809
Resources and Links: clinicaltrials.gov NCT No: NCT03616834


A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fruquintinib in Advanced Solid Tumors (Hutchison)

Treatment agent: Fruquintinib
PI: Thomas Stanton, MD
Study Coordinator: Sabine Ucik // Sabine.Ucik@stjoe.org // (707) 521-3830
Resources and Links: clinicaltrials.gov NCT No: NCT03251378


SEERPRO: A Prospective Blood Sample Collection Study to Evaluate a Panel of Protein-based Biomarkers (SEER)

Treatment agent: Single-visit blood sample collection
PI: Thomas Stanton, MD
Study Coordinator: Camille Shaffer // Camille.Shaffer@stjoe.org // (707) 521-3809
Resources and Links: Not available


A Multi- Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal and Breast Cancer

Treatment: Fruquintinib
PI: Ian Anderson, MD
Coordinator: Kayla
Resources and Links: clinicaltrials.gov NCT No: NCT03251378


Efficacy and Safety of Pemigatinib in Previously treated locally advanced/metastatic or Surgically unresectable solid tumor malignancies harboring activating FGFG Mutations or Translocations(FIGHT-207)

Treatment: Pemigatinib
PI: Ian Anderson, MD
Coordinator: Tracy
Resources and Links: clinicaltrials.gov NCT No: NCT0363184


A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Treatment: Ibrutinib, Everolimus, Docetaxel, Paclitaxel, Cetuximab, Pembrolizumab
PI: Wes Lee, MD​
Coordinator: Teresa
Resources and Links: clinicaltrials.gov NCT No: NCT02599324


A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Treatment: ladiratuzumab vedotin
PI: Ian Anderson, MD
Coordinator: Diego
Resources and Links: clinicaltrials.gov NCT No: NCT04032704


Seer-020102

PI: Manasa Vulchi, MD
Coordinator: Camille


A Study of Repotrectinib(TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Rearrangements (TRIDENT-1)

Treatment: Oral Repotrectinib
PI: Ian Anderson, MD
Coordinator: Tracy
Resources and Links: clinicaltrials.gov NCT No: NCT03093116

Our Providers

Our Locations